Home Companies Catalysts Deep Dives
Xospata gilteritinib APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Launch2018-11-28
US LOE2032-09-01
Peak Sales Est$800M
Formulations[{"id":"xospata-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":
Companies
ALPMY (ORIGINATOR)100%
Mechanism: FLT3 inhibitor
Expert: FLT3/AXL dual inhibitor for FLT3-mutated acute myeloid leukemia.
Everyday: Blocks a mutated protein that drives certain leukemias.
Targets: ["FLT3"]
Revenue History
PeriodRevenue ($M)
FY2023$413M
FY2024$453M
Programs (1)
IndicationStageKey StudyRegional Status
FLT3+ R/R AMLAPPROVEDADMIRAL[{"stage":"APPROVED","region":"US","approval_date":"2018-11-28"}]
Upcoming Catalysts (1)
Xospata - Commercial Updates 2026
Notes
FLT3 inhibitor for R/R AML. Steady growth in niche indication.
Data from Supabase · Updated 2026-03-24